EU medicines regulator rejects Eli Lilly's Alzheimer's drug
28/03/2025 10:53
March 28 (Reuters) - The European Union's drugs regulator on Friday rejected Eli Lilly's LLY.N Alzheimer's drug Kisunla, saying the risk of serious brain swelling did not outweigh the treatment's small impact on slowing cognitive decline. (Reporting by Mariam Sunny and Padmanabhan Ananthan in Bengaluru; Editing by Shreya Biswas and Sriraj Kalluvila) ((Padmanabhan.Ananthan@thomsonreuters.com Mariam.ESunny@thomsonreuters.com))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China